In Shanghai in June, the rain washed away the sultry heat and brought coolness, and as far as the eye could see, it was full of vitality and everything was lovely. In September last year, at the 2020 Academic Annual Meeting of the CSCO Expert Committee on Integrated Traditional Chinese and Western Medicine, we held the launching ceremony of the "Expert Consensus on the Treatment of Myelosuppression Caused by Chemotherapy by Integrated Traditional Chinese and Western Medicine" in Qingdao, where the green mountains and blue seas and red tiles and green trees are green. This year, in order to further improve the standardization level of integrated traditional Chinese and Western medicine in the treatment of malignant tumors in China, reduce the incidence of toxic and side effects in tumor-related treatments, improve the quality of life of patients, and ensure medical safety, Hubei Mengyang Pharmaceutical Co., Ltd. assisted in the compilation of the "Expert Consensus on the Diagnosis and Treatment of Bone Marrow Suppression Caused by Anti-tumor Drugs", which lasted three months, and the first draft of the expert consensus has been completed. At the end of last week, an expert consensus review meeting was held online and offline in Shanghai's Hongqiao Business District.
A total of 20 experts, including Professor Li Pingping from Peking University Cancer Hospital, Professor Hua Haiqing, Chairman of the CSCO Expert Committee on Integrated Traditional Chinese and Western Medicine, Vice Chairman and Secretary-General, and leaders and members of the consensus writing team participated in the meeting.
The meeting was presided over by Professor Zhang Yue, Vice Chairman of the Conference and Professor of Jilin Provincial Cancer Hospital, Professor Hua Haiqing, Chairman of the Conference and Professor of the Eastern Theater General Hospital of the People's Liberation Army, delivered a speech, and Ms. Zhou Huiying, Vice President of Administration of Mengyang Pharmaceutical, delivered a welcome speech.
In the academic exchange part, Jiang Ziyu, a member of the expert consensus compilation team and deputy director of Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine, brought "Research Progress on Bone Marrow Suppression Caused by Anti-tumor Drugs in Traditional Chinese Medicine". It is described from three parts: an overview of bone marrow suppression, the etiology and pathogenesis of traditional Chinese medicine, and the progress of traditional Chinese medicine treatment. Among them, in the progress of traditional Chinese medicine treatment, the latest RCT research results of Shengbai Oral Liquid were shared: the use of Shengbai Oral Liquid for prevention and concurrent chemotherapy has significant efficacy on the incidence and degree of neutropenia and the incidence of thrombocytopenia after chemotherapy. Then, Yao Qinghua, member of the Standing Committee of the General Assembly, leader of the expert consensus writing team, and director of Zhejiang Provincial Cancer Hospital, reported on the "consensus structure and introduction of each chapter".
After that, the participating experts had a heated discussion on the details of the content of each chapter of the consensus, and reached a certain consensus.
Myelosuppression is a common adverse reaction of antineoplastic drugs, which not only reduces the dose intensity and dose density of chemotherapy in cancer patients, but also brings adverse events such as infection and bleeding, which seriously affects the prognosis of patients. Based on the theory of "prevention of disease", TCM advocates the principle of prevention first, prevention and treatment combined, and attaches importance to the holistic concept and syndrome differentiation and treatment, which can not only prevent and treat bone marrow suppression, but also treat the tumor itself and other complications. It can be seen that the compilation of the "Expert Consensus on the Diagnosis and Treatment of Bone Myelosuppression Caused by Antineoplastic Drugs" is of great significance to improve the standardization level of integrated traditional Chinese and Western medicine in the treatment of malignant tumors, reduce the incidence of toxic and side effects in tumor-related treatments, improve the quality of life of patients, and ensure medical safety.
Mengyang Pharmaceutical has been committed to excavating the treasures of traditional medicine in the motherland, developing the classic prescriptions of famous and old Chinese medicine and the active ingredients derived from natural medicines into new drugs to benefit more patients. Through the participation of this expert consensus project, we have made it more clear that it is necessary to carry out multi-center clinical research with large samples, in line with evidence-based medical norms and the scientific evaluation system of traditional Chinese medicine, and Mengyang Pharmaceutical is also willing to actively participate in the interpretation of the scientific nature of traditional Chinese medicine, and work with all the experts who are struggling in the clinical front line to jointly explore the theory and mechanism of traditional Chinese medicine prescriptions, and contribute to the development of traditional Chinese medicine.
